Media release

DKSH transfers healthcare business in China and increases strategic focus

For many years, DKSH has pursued a niche strategy in the Chinese healthcare market. DKSH now announced an agreement to transfer this business to Warburg Pincus. The transaction emphasizes DKSH's increased strategic focus, realizing the value created over the years. DKSH continues to be present with its Consumer Goods, Performance Materials and Technology businesses in China.

Zurich, Switzerland, July 10, 2018 - DKSH, the leading Market Expansion Services provider with a focus on Asia, today announced an agreement to transfer its Healthcare business in China to Warburg Pincus.

The transfer of the healthcare business emphasizes the increased strategic focus of DKSH. The company has pursued a niche strategy in the Chinese healthcare market for many years. Reviewing its portfolio on a regular basis, DKSH has identified Warburg Pincus as the ideal new owner. Their scale and experience allows them to further take advantage of the potential in the business.

The transaction includes DKSH's pharma, consumer health and medical device businesses. Already in 2015, DKSH transferred two own pharmaceutical brands, Combizym and Hirudoid, to the Chinese pharma distributor CMS. DKSH continues to be present in China with Business Units Consumer Goods, Performance Materials and Technology.

Closing of the transaction is expected for the second half-year of 2018 and is subject to certain conditions and regulatory approvals. Assuming constant exchange rates, net sales related to the transaction were over CHF 300 million in 2017 and the purchase price is expected to be approximately CHF 100 million.

Stefan P. Butz, CEO of DKSH says: "The transfer emphasizes our increased strategic focus and China historically has been a niche market for our healthcare business. Expanding the market requires significant scale. We are pleased to transfer the business to Warburg Pincus for further expansion. We would like to thank our colleagues in China for their achievements and wish them continued success together with Warburg Pincus."

About DKSH Group

DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets. Publicly listed on the SIX Swiss Exchange since 2012, DKSH is a global company headquartered in Zurich. With 825 business locations in 37 countries - 800 of them in Asia - and 31,970 specialized staff, DKSH generated net sales of CHF 11.0 billion in 2017. DKSH was founded in 1865. With strong Swiss heritage, the company has a long tradition of doing business in and with Asia and is deeply rooted in communities and businesses across Asia Pacific.

About Warburg Pincus

Warburg Pincus LLC is a leading global private equity firm focused on growth investing. The firm has more than $45 billion in private equity assets under management. Founded in 1966, Warburg Pincus has raised 17 private equity funds which have invested more than $68 billion in over 820 companies in more than 40 countries. Warburg Pincus is an experienced investor in healthcare and consumer sector, with more than $15.0 billion invested in over 200 healthcare and consumer globally. With over 24 years of track record investing in China, Warburg Pincus has backed growth of some of the leading healthcare companies including Lepu Medical, Wuxi Pharma, China Biologic Products, PW Medtech Group PWM and Amcare Women's & Children's Hospital.

For further information please contact:

DKSH Holding Ltd.

Till Leisner

Head, Group Investor & Media Relations

Phone +41 44 386 7315

till.leisner@dksh.com

Dominique Nadelhofer

Senior Manager, Group Media Relations

Phone +41 44 386 7228

dominique.nadelhofer@dksh.com


Image (JPG)
Media release in English and Chinese (PDF)



Provider
 Channel
 Contact
Tensid EQS Ltd., Switzerland
www.tensid.ch


 newsbox.ch
www.newsbox.ch


 Provider/Channel related enquiries
marco@tensid.ch
+41 41 763 00 50